Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 0.57 |
| ▸ | CCR1 | P32246 | 5/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2210819 | 1.00 | CCR3 (0.57) | CCR3CCR1SIGMAR1DRD2ADRA1A | |
| SCHEMBL2212735 | 0.95 | CCR3 (0.55) | CCR3CCR1SIGMAR1DRD2ADRA1A | |
| SCHEMBL12511802 | 0.94 | CCR3 (0.58) | CCR3CCR1SIGMAR1DRD2ADRA1A | |
| SCHEMBL2213254 | 0.93 | CCR3 (0.56) | CCR3CCR1SIGMAR1DRD2ADRA1A | |
| SCHEMBL2213261 | 0.93 | CCR3 (0.56) | CCR3CCR1SIGMAR1DRD2ADRA1A | |
| SCHEMBL2210847 | 0.93 | CCR3 (0.56) | CCR3CCR1SIGMAR1DRD2ADRA1A | |
| SCHEMBL2211850 | 0.92 | CCR3 (0.54) | CCR3CCR1SIGMAR1DRD2ADRA1A | |
| SCHEMBL2211556 | 0.92 | CCR3 (0.55) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL2212053 | 0.91 | CCR3 (0.55) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL2215033 | 0.91 | CCR3 (0.56) | CCR3CCR1SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | CCR3 21/4885CCR1 11/4885SIGMAR1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.